Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia
British Journal of Haematology · 16.11.2026
DOI: 10.1111/bjh.70925 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 16.11.2026. Verfasst von Kiyomi Mashima und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, CLL Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Tree of Life team of the Jimmy Fund Walk, Japan Society for the Promotion of Science (JSPS) Overseas Research Fellowship.
Abstract (Originalsprache)
We retrospectively analysed 646 chronic lymphocytic leukaemia (CLL) patients treated with Bruton tyrosine kinase inhibitors (BTKis) at Dana‐Farber Cancer Institute from 2014 to 2023. Among them, 122 underwent next‐generation sequencing (NGS) during or at the next office visit after BTKi therapy (ibrutinib [IBR], 85; acalabrutinib [ACA], 23; pirtobrutinib [PIR], 9; vecabrutinib [VEC], 1; zanubrutinib [ZANU], 4). Compared with the non‐progressor (NP) group ( N = 75), patients with NGS at progression (PD group, N = 47) more commonly had 17p deletion, complex karyotype, heavier prior treatment exposure and prior exposure to a different BTKi before the current regimen. We found 321 mutations in 67 genes, with more mutations in the PD group (231 mutations), including 39 BTK ( BTK C481S/F/R/Y, L528W and T474I/L) and 26 phospholipase C gamma 2 ( PLCG2 ) mutations. Among the 12 PD patients with serial samples, all acquired new or expanded BTK or TP53 mutations. Complex karyotype, specifically 8p loss, was significantly enriched in the PD group. tumour protein p53 ( TP53 ), splicing factor 3b subunit 1 ( SF3B1 ), protein phosphatase, Mg 2 + /Mn 2 + dependent 1D ( PPM1D ) and notch receptor 2 ( NOTCH2 ) mutations were also significantly more prevalent in the PD group (all p < 0.05). Additionally, pathogenic mitogen‐activated protein kinase (MAPK) pathway mutations trended more common and had higher variant allele frequencies (VAFs) in the PD group ( p = 0.047). These findings suggest that TP53 aberration and 8p‐loss‐associated complex karyotype, as well as several non‐BTK driver mutations, are enriched in BTKi‐resistant patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, CLL Center, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
- Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Kiyomi Mashima, Binu Kandathilparambil Sasi, Saurabh Yadav, Uday Aditya Sarkar, Colin McNulty, Ava M Kominski, Paige R Fitzgerald, Ava Bidgoli, Paulina Predko, John-Hanson Machado, Matthew S Davids, Jennifer R Brown
Förderung
- NCI NIH HHS
- Tree of Life team of the Jimmy Fund Walk
- Japan Society for the Promotion of Science (JSPS) Overseas Research Fellowship
- National Cancer Institute
- Japan Society for the Promotion of Science
Zitieren
APA
Mashima, K., Fernandes, S. M., Mikhaleva, M., Azevedo, R. S., Martindale, S., Sasi, B. K., Yadav, S., Sarkar, U. A., Fardoun, R., Sun, X., McNulty, C., Kominski, A. M., Fitzgerald, P. R., Bidgoli, A., Predko, P., Shupe, S., Machado, J. H., Naeem, A., Ahn, I. E., …, & Brown, J. R. (2026). Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia. British Journal of Haematology. https://doi.org/10.1111/bjh.70925
Vancouver
Mashima K, Fernandes SM, Mikhaleva M, Azevedo RS, Martindale S, Sasi BK, et al. Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia. British Journal of Haematology. 2026. doi:10.1111/bjh.70925
BibTeX
@article{Mashima2026,
author = {Mashima, Kiyomi and Fernandes, Stacey M and Mikhaleva, Mariia and Azevedo, Roberta Santos and Martindale, Stephen and Sasi, Binu Kandathilparambil and Yadav, Saurabh and Sarkar, Uday Aditya and Fardoun, Rayan and Sun, Xinhao and McNulty, Colin and Kominski, Ava M and Fitzgerald, Paige R and Bidgoli, Ava and Predko, Paulina and Shupe, Samantha and Machado, John-Hanson and Naeem, Aishath and Ahn, Inhye E and Davids, Matthew S and Brown, Jennifer R},
title = {Complex karyotype and non‐ BTK driver mutations associated with BTK inhibitor resistance in chronic lymphocytic leukaemia},
journal = {British Journal of Haematology},
year = {2026},
doi = {10.1111/bjh.70925}
}
EUVIMED